HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $22 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $22 price target.
Credit Suisse Maintains Outperform on Ikena Oncology, Lowers Price Target to $13
Credit Suisse analyst Judah Frommer maintains Ikena Oncology (NASDAQ:IKNA) with a Outperform and lowers the price target from $16 to $13.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Kala Pharmaceuticals (NASDAQ:KALA) stock moved upwards by 68.1% to $6.59 during Tuesday’s after-market session. Kala Pharmaceuticals’s trading…
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday’s Mid-Day Session
Gainers
Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
Ikena Oncology Announces New Cancer Program, Shelves Early Asset For Colorectal Cancer
Ikena Oncology Inc (NASDAQ: IKNA) nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway.
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 236 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 96 stocks hit new 52-week lows.
Ikena Oncology To Present Initial Phase 1a/b Results From Novel AHR Inhibition Program At The 2022 Society For Immunotherapy Of Cancer 37th Annual Meeting
Ikena Oncology, Inc. (NASDAQ:IKNA, ", Ikena", )))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company's Aryl
